LifeMD (LFMD) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of LifeMD (NASDAQ: LFMD) recently:

• 12/29/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – LifeMD was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 12/15/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – LifeMD had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – LifeMD was given a new $8.00 price target on by analysts at Loop Capital.
• 11/22/2025 – LifeMD was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/20/2025 – LifeMD was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 11/19/2025 – LifeMD had its price target lowered by analysts at HC Wainwright from $13.00 to $9.00. They now have a “buy” rating on the stock.
• 11/19/2025 – LifeMD had its price target lowered by analysts at KeyCorp from $12.00 to $8.00. They now have an “overweight” rating on the stock.
• 11/19/2025 – LifeMD had its price target lowered by analysts at Mizuho from $8.00 to $6.00. They now have a “neutral” rating on the stock.
• 11/18/2025 – LifeMD had its price target lowered by analysts at Lake Street Capital from $14.00 to $8.00. They now have a “buy” rating on the stock.
• 11/18/2025 – LifeMD had its price target lowered by analysts at B. Riley from $12.00 to $10.00. They now have a “buy” rating on the stock.
• 11/18/2025 – LifeMD had its price target lowered by analysts at BTIG Research from $18.00 to $10.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at LifeMD

In other news, CMO Jessica Friedeman sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $3.61, for a total transaction of $54,150.00. Following the transaction, the chief marketing officer directly owned 205,000 shares in the company, valued at approximately $740,050. This trade represents a 6.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 18.40% of the company’s stock.

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.